A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses.

Trial Profile

A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Asthma; Respiratory tract infections; Viral infections
  • Focus Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors Synairgen
  • Most Recent Events

    • 18 Jul 2013 Biomarker results will be presented at the 23rd Annual Congress of the European respiratory Society (ERS-2013) according to a Synairgen media release.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 19 Apr 2012 Actual patient number (134) added as reported in a Synairgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top